Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more
Jeil Pharmaceutical Co Ltd (271980) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.054x
Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has a cash flow conversion efficiency ratio of 0.054x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩13.23 Billion) by net assets (₩243.59 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jeil Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Jeil Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jeil Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NSTS Bancorp Inc
NASDAQ:NSTS
|
0.036x |
|
GeneOne Life Science Inc
KO:011000
|
-0.065x |
|
Unitron Tech Co Ltd
KQ:142210
|
0.099x |
|
NVR (NVE.SG)
STU:NVE
|
0.084x |
|
F & M Bank Corp
OTCQX:FMBM
|
0.069x |
|
Grown Rogue International Inc
OTCQB:GRUSF
|
0.015x |
|
Frontage Holdings Corporation
PINK:FGHQF
|
0.047x |
|
Future Vision II Acquisition Corporation Units
NASDAQ:FVNNU
|
0.000x |
Annual Cash Flow Conversion Efficiency for Jeil Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Jeil Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩219.32 Billion | ₩3.21 Billion | 0.015x | +146.19% |
| 2023-12-31 | ₩157.03 Billion | ₩-4.98 Billion | -0.032x | +67.42% |
| 2022-12-31 | ₩155.60 Billion | ₩-15.15 Billion | -0.097x | -185.29% |
| 2021-12-31 | ₩167.35 Billion | ₩19.10 Billion | 0.114x | +203.36% |
| 2020-12-31 | ₩172.48 Billion | ₩-19.05 Billion | -0.110x | -164.84% |
| 2019-12-31 | ₩170.04 Billion | ₩28.96 Billion | 0.170x | +46.80% |
| 2018-12-31 | ₩184.93 Billion | ₩21.45 Billion | 0.116x | +590.46% |
| 2017-12-31 | ₩177.99 Billion | ₩-4.21 Billion | -0.024x | -- |